Information Provided By:
Fly News Breaks for November 8, 2019
COLL
Nov 8, 2019 | 07:31 EDT
SunTrust analyst Gregg Gilbert raised his price target on Collegium Pharmaceutical to $22 and kept his Buy rating after its Q3 results, saying that with announced access wins, he is raising his modeled Xtampza ER market share for long-acting opioid to 5% from 4.3% in 2020. The analyst warns however that after spiking over 30% yesterday, the stock may "tread water" for a bit as investors consider the company's exposure to opioid litigation.
News For COLL From the Last 2 Days
There are no results for your query COLL